232 related articles for article (PubMed ID: 36647580)
1. Discovery of All-d-Peptide Inhibitors of SARS-CoV-2 3C-like Protease.
Eberle RJ; Sevenich M; Gering I; Scharbert L; Strodel B; Lakomek NA; Santur K; Mohrlüder J; Coronado MA; Willbold D
ACS Chem Biol; 2023 Feb; 18(2):315-330. PubMed ID: 36647580
[TBL] [Abstract][Full Text] [Related]
2. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
[TBL] [Abstract][Full Text] [Related]
3. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
[TBL] [Abstract][Full Text] [Related]
4. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
[TBL] [Abstract][Full Text] [Related]
6. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577
[TBL] [Abstract][Full Text] [Related]
7. Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2.
Ren P; Yu C; Zhang R; Nie T; Hu Q; Li H; Zhang X; Zhang X; Li S; Liu L; Dai W; Li J; Xu Y; Su H; Zhang L; Liu H; Bai F
Eur J Med Chem; 2023 Mar; 249():115129. PubMed ID: 36702052
[TBL] [Abstract][Full Text] [Related]
8. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
11. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
[TBL] [Abstract][Full Text] [Related]
12. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
[TBL] [Abstract][Full Text] [Related]
13. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
Bao HL; Tu G; Yue Q; Liu P; Zheng HL; Yao XJ
Chem Biol Drug Des; 2023 Oct; 102(4):857-869. PubMed ID: 37563791
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.
Amblard F; LeCher JC; De R; Zhou S; Liu P; Goh SL; Tao S; Patel D; Downs-Bowen J; Zandi K; Zhang H; Chaudhry G; McBrayer T; Muczynski M; Al-Homoudi A; Engel J; Lan S; Sarafianos SG; Kovari LC; Schinazi RF
Eur J Med Chem; 2024 Mar; 268():116263. PubMed ID: 38432056
[TBL] [Abstract][Full Text] [Related]
16. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites.
Iketani S; Hong SJ; Sheng J; Bahari F; Culbertson B; Atanaki FF; Aditham AK; Kratz AF; Luck MI; Tian R; Goff SP; Montazeri H; Sabo Y; Ho DD; Chavez A
Cell Host Microbe; 2022 Oct; 30(10):1354-1362.e6. PubMed ID: 36029764
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Biochemical Evaluation of 8
Wu J; Feng B; Gao LX; Zhang C; Li J; Xiang DJ; Zang Y; Wang WL
Molecules; 2022 May; 27(10):. PubMed ID: 35630836
[TBL] [Abstract][Full Text] [Related]
18. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
[TBL] [Abstract][Full Text] [Related]
19. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
20. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
Hicks EG; Kandel SE; Lampe JN
Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]